



FULBRIGHT & JAWORSKI L.L.P.

A REGISTERED LIMITED LIABILITY PARTNERSHIP
600 CONGRESS AVENUE, SUITE 2400
AUSTIN, TEXAS 78701-3271
WWW.FULBRIGHT.COM

DAVID L. PARKER
PARTNER
DPARKER@FULBRIGHT.COM

DIRECT DIAL: (512) 536-3055
TELEPHONE: (512) 474-5201
FACSIMILE: (512) 536-4598

March 3, 2005

CERTIFICATE OF MAILING 37 C.F.R. 1.8

I certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

March 3, 2005

Date

David L. Parker

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

RE: *U.S. Patent Application No. 10/644,418 entitled "TOCOPHEROLS, TOCOTRIENOLS, OTHER CHROMAN AND SIDE CHAIN DERIVATIVES AND USES THEREOF" – Bob G. Sanders et al.*
Our reference: CLFR:177USD1

Sir:

Enclosed for filing in the above-referenced patent application is an Information Disclosure Statement, Form PTO-1449, and references B1-B17 and C1-C8.

No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to the enclosed materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CLFR:177USD1.

Please date stamp and return the enclosed postcard evidencing receipt of these materials.

Respectfully submitted,

David L. Parker
Reg. No. 32,165

DLP/kvp
Encl.: as noted



PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:
Bob G. Sanders et al.

Serial No.: 10/644,418

Filed: August 20, 2003

For: TOCOPHEROLS, TOCOTRIENOLS,
OTHER CHROMAN AND SIDE CHAIN
DERIVATIVES AND USES THEREOF

Group Art Unit: 1614

Examiner: Unknown

Atty. Dkt. No.: CLFR:177USD1

CERTIFICATE OF MAILING
37 C.F.R. 1.8

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail in an envelope addressed to: MS AMENDMENT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date below:

March 3, 2005
Date


David L. Parker

INFORMATION DISCLOSURE STATEMENT

MS AMENDMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, Virginia 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56, it is respectfully requested that this Information Disclosure Statement be entered and the documents listed on attached Form PTO-1449 be considered by the Examiner and made of record. Copies of cited U.S. patents, U. S. patent application publications and co-pending U.S. patent applications have not been enclosed subject to the waiver regarding the requirement under 37 C.F.R. § 1.98(a)(2)(i) stated in the Official Gazette Notice dated August 5, 2003 regarding patent applications filed on or after June 30, 2003.


In accordance with 37 C.F.R §§ 1.97(g), (h), this Information Disclosure Statement is not to be construed as a representation that a search has been made, and is not to be construed to be an admission that the information cited is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

This application is a application of Serial No. 09/502,592, filed February 11, 2000, which is a continuation-in-part of 09/404,001 filed September 23, 1999 and is relied upon for an earlier filing date under 35 U.S.C. § 120. In accordance with Rule 37 C.F.R. § 1.98(d) only copies of those documents not previously cited and submitted to the Patent and Trademark Office in prior application Serial No. are enclosed for the convenience of the Examiner.

The present Information Disclosure Statement is being filed prior to the receipt of a first Official Action reflecting an examination on the merits, and hence is believed to be timely filed in accordance with 37 C.F.R § 1.97(b). No fees are believed to be due in connection with the filing of this Information Disclosure Statement, however, should any fees under 37 C.F.R. §§ 1.16 to 1.21 be deemed necessary for any reason relating to these materials, the Commissioner is authorized to deduct the appropriate fees from Fulbright & Jaworski Deposit Account No.: 50-1212/CLFR:177USD1.

Applicants respectfully request that the listed documents be made of record in the present case

Respectfully submitted,



David L. Parker
Reg. No. 32,165
Attorney for Applicants

FULBRIGHT & JAWORSKI L.L.P.
600 Congress Avenue, Suite 2400
Austin, Texas 78701
(512) 474-5201

Date: March 3, 2005

Form PTO-1449 (modified)

Atty. Docket No.
CLFR:177USD1Serial No.
10/644,418

List of Patents and Publications for Applicant's

Applicant
Bob G. Sanders *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
August 20, 2003Group:
1614U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 2*Other Art
See Page 3

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	3,869,477	3/4/75	Shindo <i>et al.</i>	260	345.5	1/30/73
	A2	4,181,725	1/1/80	Voorhees <i>et al.</i>	424	258	5/2/77
	A3	4,320,141	3/16/82	Komatsu <i>et al.</i>	424	284	12/14/78
	A4	4,457,918	7/3/84	Holick <i>et al.</i>	424	180	5/12/82
	A5	4,617,317	10/14/86	Bennet	514	458	10/31/84
	A6	4,645,845	2/24/87	Gehrken <i>et al.</i>	549	407	3/12/84
	A7	4,665,204	5/12/87	Wirth	549	410	6/27/85
	A8	4,873,088	10/10/89	Mayhew <i>et al.</i>	424	450	7/13/87
	A9	4,895,719	1/23/90	Radhakrishnan <i>et al.</i>	424	45	3/6/87
	A10	5,114,957	5/19/92	Hendler <i>et al.</i>	514	356	5/8/90
	A11	5,135,945	8/4/92	Robinson <i>et al.</i>	514	456	6/5/91
	A12	5,260,294	11/9/93	Walser	514	230	5/27/92
	A13	5,315,017	5/24/94	Le Baut <i>et al.</i>	549	408	5/1/92
	A14	5,393,775	2/28/95	Le Baut <i>et al.</i>	514	456	9/7/93
	A15	5,403,834	4/4/95	Malfroy-Camine <i>et al.</i>	514	185	12/7/92
	A16	5,545,660	8/13/96	Grisar <i>et al.</i>	514	458	3/12/93
	A17	5,610,180	3/11/97	Fariss	514	458	8/8/94
	A18	5,650,404	7/22/97	Ogata <i>et al.</i>	514	100	7/18/95
	A19	5,747,162	5/5/98	Temple <i>et al.</i>	428	395	2/7/97
	A20	5,827,878	10/27/98	Makishima <i>et al.</i>	514	458	6/27/97
	A21	5,917,060	6/29/99	Rosenau <i>et al.</i>	549	408	12/17/97
	A22	5,919,818	7/6/99	Lane <i>et al.</i>	514	458	12/16/97
	A23	5,990,322	11/23/99	Lee <i>et al.</i>	549	410	3/9/99

25508520.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)

Atty. Docket No.
CLFR:177USD1Serial No.
10/644,418

List of Patents and Publications for Applicant's

Applicant
Bob G. Sanders *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:
August 20, 2003Group:
1614U.S. Patent Documents
*See Page 1*Foreign Patent Documents
*See Page 2*Other Art
See Page 3

U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A24	6,022,560	2/8/00	Yazdi <i>et al.</i>	424	450	6/8/98
	A25	6,127,382	10/3/00	Beard <i>et al.</i>	514	311	8/16/99
	A26	6,133,312	10/17/00	Elson	514	458	10/17/00
	A27	6,417,223	7/9/02	Sanders <i>et al.</i>	514	456	9/23/99
	A28	6,645,998	11/11/03	Sanders <i>et al.</i>	514	456	4/12/02
	A29	6,770,672	8/3/04	Sanders <i>et al.</i>	514	458	2/1/00
	A30	2003/0236301	12/25/03	Sanders <i>et al.</i>	514	458	12/19/02
	A31	2004/0097431	5/20/04	Sanders <i>et al.</i>	514	27	10/28/03

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	DE 4304303	8/18/04	Germany			Abstract
	B2	EP 0436911	7/17/90	Europe			English
	B3	EP 0506048	9/30/92	Europe			English
	B4	EP 0636618	2/01/95	Europe			Abstract
	B5	EP 0731125	1/02/97	Europe			Abstract
	B6	EP 0754458	2/22/97	Europe			English
	B7	EP 0768314	4/16/97	Europe			English
	B8	JP 01041727	2/14/89	Japan			Abstract
	B9	JP 04229269	8/18/92	Japan			Abstract
	B10	JP 55076871	6/10/80	Japan			Abstract
	B11	JP 63303049	12/9/88	Japan			Abstract
	B12	JP 9301969	11/25/97	Japan			Abstract

25508520.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

INFORMATION DISCLOSURE STATEMENT — PTO-1449 (MODIFIED)

Form PTO-1449 (modified)

Atty. Docket No.

Serial No.

CLFR:177USD1

10/644,418

List of Patents and Publications for Applicant's

Applicant

Bob G. Sanders *et al.*

INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)

Filing Date:

August 20, 2003

Group:

1614

U.S. Patent Documents

See Page 1

Foreign Patent Documents

See Page 2

Other Art

See Page 3

Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B13	WO 00/16772	3/30/00	WIPO			English
	B14	WO 01/58889	8/16/01	WIPO			English
	B15	WO 97/41852	11/13/97	WIPO			English
	B16	WO 98/17246	4/30/98	WIPO			English
	B17	WO 99/24417	5/20/99	WIPO			English

Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Arya <i>et al.</i> , "Design and synthesis of analogs of vitamin E: antiproliferative activity against human breast adenocarcinoma cells," <i>Bioorg. Med. Chem. Lett.</i> , 8:2433-2438, 1998.
	C2	Djuric <i>et al.</i> , "Growth inhibition of MCF-7 and MCF-10A human breast cells by alpha-tocopheryl hemisuccinate, cholesteryl hemisuccinate and their ether analogs," <i>Cancer Lett.</i> , 111:133-139, 1997.
	C3	Fariss <i>et al.</i> , "The selective antiproliferative effects of alpha-tocopheryl hemisuccinate and cholesteryl hemisuccinate on murine leukemia cells result from the action of the intact compounds," <i>Cancer Res.</i> , 54:3346-3351, 1994.
	C4	Koyama <i>et al.</i> , "Synthesis of fluorine analogues of vitamin E. II. Synthesis of 2-(3-chloropropyl)-2,5,7,8-tetramethyl-6-chromanol and its application for stereocontrolled Wittig reaction with trifluoromethyl ketones," <i>Chem. Pharm. Bull.</i> , 36:2950-2954, 1988.
	C5	Prasad <i>et al.</i> , "Effects of tocopherol (vitamin E) acid succinate on morphological alterations and growth inhibition in melanoma cells in culture," <i>Cancer Res.</i> , 42:550-555, 1982.
	C6	Urano <i>et al.</i> , "Synthesis of dl- α -tocopherol and dl- α -tocotrienol," <i>Chem. Pharm. Bull.</i> , 31:4341-4345, 1983.
	C7	Welch <i>et al.</i> , "Syntheses and activities of antioxidant derivatives of retinoic acids," <i>J. Med. Chem.</i> , 25:81-84, 1981.
	C8	Will <i>et al.</i> , "Attachment of vitamin E derivatives to oligonucleotides during solid-phase synthesis," <i>Tetrahedron Lett.</i> 33:2729-2732, 1992.

25508520.1

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.